---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000055"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-09-10T12:17:34+00:00"
generated_at: "2026-09-10T12:20:11.288475+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oncolytics announces positive preclinical results for pelareorep with pan-RAS inhibitor in colorectal cancer

## Summary
- Pelareorep + pan-RAS inhibitor reduced tumor growth vs control in RAS-driven colorectal cancer model.
- Greatest tumor reductions in RAS inhibitor and combination groups; no antagonism between therapies.
- Findings support further evaluation of optimized pelareorep dosing with RAS inhibitors to delay resistance.
- Company plans expanded preclinical studies across dosing schedules and RAS-driven tumor models.

## SEC filing metadata
- accession: 0001129928-26-000055
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-09-10T12:17:34+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/0001129928-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/oncy-20260910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000055
- JSON: https://secwatch.observer/filing/0001129928-26-000055.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.